Biotech

All Articles

OS Therapies refiles $6M IPO to money HER2 medicine, preclinical ADCs

.Operating system Therapies will definitely note on the NYSE American supply swap today through a $6...

ALX's fizzling CD47 feedback cost sends out sell spiraling down

.ALX Oncology's period 2 gastric cancer cells reaction rate has diminished. After observing its CD47...

Ionis centers eye condition coming from aim ats of Roche-partnered prospect after records dissatisfy

.One More of Ionis Pharmaceuticals' essential midphase readouts has actually disappointed desires, u...

Biogen's chief executive officer said no risky sell 2023. He's ready to be bold

.While Biogen's pharma peers are actually seeking for late-stage assets with little bit of danger, c...

Instil refills pipe in $2B biobucks handle ImmunOnco

.Instil Bio has actually been a biotech looking for a pipe after it scrapped its own lead assets ove...

Biogen bows out Denali Alzheimer's collab

.Biogen has actually returned rights to a very early Alzheimer's ailment program to Denali Therapies...

Takeda taps brand-new head of US oncology business-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our summary of significant leadership hirings, shootings...

Vertex, hammered by AATD once more, drops 2 possessions on dispose of heap

.Vertex's attempt to alleviate an unusual hereditary illness has actually struck an additional drawb...

Vir increases 3 T-cell engagers coming from Sanofi, gives up 25% of workers

.Vir Medical's second-quarter profits document had not been short of huge information. The provider ...

Galapagos stops CAR-T cell treatment litigation over Parkinsonism instance

.Galapagos has stopped application in a trial of a BCMA-directed CAR-T cell treatment, pushing the b...